KCM
AEGR

Kingdon Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Kingdon Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-45,000
Closed -$1.4M – 207
2014
Q2 		$1.44M Buy
45,000
+5,000
+13% +$186K 0.06% 175
2014
Q1 		$1.84M Sell
40,000
-418,410
-91% -$24.5M 0.09% 160
2013
Q4 		$32.5M Sell
458,410
-30,771
-6% -$2.35M 1.49% 10
2013
Q3 		$41.9M Sell
489,181
-10,666
-2% -$904K 2.06% 7
2013
Q2 		$31.7M Buy
+499,847
New +$26.5M 1.87% 6

Other funds holding AEGR

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Kingdon Capital Management's AEGR Position: Q3 2014 in Review

Kingdon Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2014, closing a stake of 45,000 shares — an estimated $1.4M sold.

Kingdon Capital Management first reported a position in AEGR in Q2 2013 and held it in 5 quarters. The position peaked at $41.9M in Q3 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

  • Kingdon Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Kingdon Capital Management sold 45,000 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $1.4M.
  • Kingdon Capital Management first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Kingdon Capital Management's Aegerion Pharmaceuticals position peaked at $41.9M in Q3 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on Kingdon Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.